Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062738 · ClinicalTrials.gov registry record · Phase 2
Treatment of Depression in Parkinson's Disease Trial
A Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT00062738 is a Phase 2 study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 52 participants.
The verdict
NCT00062738, a Phase 2 study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate the effectiveness and safety of two antidepressants--nortriptyline and paroxetine, compared to placebo in patients with Parkinson's disease and depression.
Interventions
- OTHER placebo
- DRUG Nortriptyline
- DRUG paroxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2003-06 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062738
The ClinicalTrials.gov registry entry for NCT00062738 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00062738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00062738 about?
NCT00062738 is a clinical study titled "Treatment of Depression in Parkinson's Disease Trial". The goal of this study is to evaluate the effectiveness and safety of two antidepressants--nortriptyline and paroxetine, compared to placebo in patients with Parkinson's disease and depression.
What is the current status of trial NCT00062738?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2003-06. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00062738?
The interventions under investigation include: placebo (OTHER), Nortriptyline (DRUG), paroxetine (DRUG).
Who is sponsoring clinical trial NCT00062738?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.